Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...